Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 17 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 14 15 16 17 presentations: 1 to 25 of 425
Introduction
Padmanee Sharma
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
T-cell therapy targeting unique cancer mutations
Steven A Rosenberg
National Cancer Inst., Bethesda, MD, United States
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
Redirecting T cells for cancer immunotherapy using next-generation bispecific antibodies and fusion proteins
Pablo Umana
Roche Innovation Center Zurich, Zurich, Switzerland
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
Taming the beast: Strategies to target the immune-suppressive macrophage to enhance cancer immune therapy
Judith A Varner
UCSD Moores Cancer Ctr., La Jolla, CA, United States
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
Mismatch repair deficiency: A connection between the immune system and cancer genetics
Dung T Le
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
Wrap-up and opportunities for the future
Padmanee Sharma
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 8:15 AM-10:15 AM
The evolving landscape of biomarker selection in immunotherapy treatment decisions
Leena Gandhi
Lilly Oncology, Boston, MA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Predicting immunotherapy response with protein-based tools: PD-L1 and beyond
David L. Rimm
Yale Univ. School of Medicine, New Haven, CT, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Cancer immunoediting: Framing response and resistance in immunotherapy
Gavin P. Dunn
Washington Univ. School of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Improving precision immuno-oncology using novel technologies
David A. Barbie
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Cancer therapeutics: A view from the microbiota
Christian Jobin
Univ. of Florida, Gainesville, FL, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Dynamic monitoring of the dysbiotic microbiome
Jonathan Braun
Mt. Sinai Medical Center, Los Angeles, CA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Identification and targeting microbial vulnerabilities
Ami S Bhatt
Stanford Medical School, Stanford, CA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Encapsulated fecal transplant: It's not just for Clostridium difficile any more!
Elizabeth L Hohmann
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on March 29, 2019 3:00 PM-5:00 PM
Discovery of BLU-667 for RET driven cancers
Jason Brubaker
Blueprint Medicines, Cambridge, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Discovery and development of USP7 inhibitors
Tim Harrison
Almac Discovery, Belfast, Ireland
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Identification and optimization of chemical series that lead to discovery of erdafitinib: A potent pan-fibroblast growth factor receptor (FGFR) inhibitor
Patrick Angibaud
Janssen R & D, Val-de-Reuil, France
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Development of potent and selective CD73 inhibitors: Discovery and characterization of AB680
Jenna Jeffrey
Arcus Biosciences, Inc., Hayward, CA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
How to develop trial objectives: Translation of science from bench to bedside to bench
Patricia M LoRusso
Yale Cancer Center, New Haven, CT, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Modernizing eligibility criteria for oncology clinical trials
Tatiana Prowell
U.S. Food and Drug Administration and Johns Hopkins Kimmel Cancer Center, Silver Spring, MD, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Biostatistical principals of clinical trial design
Mithat Gonen
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Designing meaningful and impactful clinical trials
Jyoti D Patel
Univ. of Chicago Medical Ctr., Chicago, IL, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
The changing landscape of oncology drug development
David S Hong
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
GO/NO GO decisions in cancer drug discovery: Has the decision making process evolved?
Nancy E. Kohl
Consultant, Wellesley, MA, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
Insights from a clinical development prediction algorithm: What we measure matters
David Feltquate
Bristol-Myers Squibb, New York, NY, United States
from AACR Annual Meeting 2019 on March 30, 2019 8:00 AM-10:00 AM
<< first | < prev page: of 17 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 14 15 16 17 presentations: 1 to 25 of 425